We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Entirely independent, we are able to reinvest an average of 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular, immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology – number 6 worldwide. Oncology has become a top priority in recent years.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health.
Operating in 149 countries, we have over 21,000 employees worldwide. We are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.
With 100 million patients treated worldwide by our medicinal products on a daily basis, we are keenly aware of our responsibilities to patients, doctors, and healthcare professionals. They are the motivating force behind our daily drive for innovation as a provider of therapeutic progress.
Servier Australia is the local subsidiary of the Servier group, a leading French-based international pharmaceutical company. Our head office is located in Hawthorn, Victoria. In Australia, 120 employees work across the business in areas such as sales and marketing, medical, learning and development as well as in key business functions such as HR and finance. Our medicines currently available fit into 4 therapeutic areas: cardiovascular disease, oncology, diabetes and more recently, neuropsychiatric disorders such as depression and schizophrenia. The Australian International Centre for Therapeutic Research also operates out of our Hawthorn office. The Centre was the first to be opened by Servier outside of Europe and manages Phase I, II and III clinical trials in collaboration with investigators based in research hospitals, general practices and Phase I units across Australia. It also implements non-clinical research collaborations and strategic alliances with leading academic facilities, research institutes and biotechnology companies throughout Australia.